Theralase Completes Funding Round and Issues Stock Options

Theralase Technologies (TSE:TLT) has released an update.

Theralase Technologies Inc., a pharmaceutical company focusing on treatments for cancers, bacteria, and viruses, has concluded a non-brokered private placement, raising $544,000 CAD through the issuance of units. The funds will support their ongoing Phase II clinical study for bladder cancer, preclinical research, and general corporate purposes. Additionally, the company has granted stock options to its directors, officers, and employees as part of its stock option plan.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.